Deep Value

Grace Therapeutics, Inc. (GRCE): When Execution, Not Biology, Drives Value

A regulatory event thesis on IV nimodipine, ICU economics, and approval-then-optionality in aneurysmal subarachnoid hemorrhage

Jan 29 • AT Investment Research

Chicago Rivet & Machine Co. (NYSEAMERICAN: CVR): When “Cheap” Becomes a Cage

Why asset backing, family control, and cyclical earnings turn CVR into a value trap for minority shareholders

Jan 26 • AT Investment Research

A Trip Down Memory Lane: An Anatomy of a Perfect Luxury Mispricing

Revisiting My Burberry Plc Investment — A Masterclass in Brand Equity, Optionality, and Timing

Dec 1, 2025 • AT Investment Research

The Quiet Winner of the Reshoring Boom: Why the Market Has It Wrong on Key Tronic (KTCC)

Cash-flow positive, strategically positioned, and trading like it’s distressed — Key Tronic’s $15 intrinsic value story defies market perception

Oct 19, 2025 • AT Investment Research

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts